首页> 外文期刊>Journal of mass spectrometry: JMS >Quantification of protein markers monitoring the pre-analytical effect of blood storage time before plasma isolation using N-15 metabolically labeled recombinant proteins
【24h】

Quantification of protein markers monitoring the pre-analytical effect of blood storage time before plasma isolation using N-15 metabolically labeled recombinant proteins

机译:用N-15代谢标记的重组蛋白监测血浆隔离前血液储存时间前血液储存时间的预分析效果的定量

获取原文
获取原文并翻译 | 示例
           

摘要

In the hospital, blood samples are collected to monitor patients' health states, and thus various protein-based clinical methods have been developed. However, some proteins are found to change in abundances during the process of blood collection and storage. In order to account such pre-analytical effects, we performed liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM-MS) on 15 selected proteins in plasma samples prepared by varying storage time and temperature of whole blood prior to plasma isolation. Two cytosolic proteins, profilin-1 (PFN1) and thymosin beta-4 (TMSB4X), were absolutely quantified using N-15-labeled recombinant proteins spiked externally. The other 13 proteins were quantified in a relative way compared with the two reference proteins. Triplicated LC-MRM-MS measurements showed that the median CV of MRM peak areas was 5.7%. The amounts of PFN1 and TMSB4X increased rapidly depending on the storage time between blood collection and plasma preparation. It indicates the leakage of cellular components into the plasma fraction. Relative quantification further revealed that five proteins including PFN1, S10A8, S10A9, S10A11, and TMSB4X showed significant difference (P0.05). We further monitored PFN1 and TMSB4X on 40 samples collected for protein diagnostics under a typical clinical study condition. Compared with the plasma samples prepared within a day, the level of both PFN1 and TMSB4X increased in the plasma samples prepared from the blood collected the day before and kept overnight at 4 degrees C (0.51 to 3.11g/mL for PFN1 and 0.98 to 5.36g/mL for TMSB4X in average). Our result suggests an effort of assuring plasma quality for accurate protein-based diagnosis or biomarker discovery and validation.
机译:在医院,收集血液样本以监测患者的健康状态,因此已经开发了各种基于蛋白质的临床方法。然而,发现一些蛋白质在血液收集和储存过程中发生丰富。为了考虑这种预分析效果,我们在通过在等离子体隔离之前通过改变储存时间和全血的温度而制备的等离子体样品中的15种选定的蛋白质进行液相色谱多反应监测质谱(LC-MRM-MS)。使用外部掺入的N-15标记的重组蛋白,绝对量化两种细胞溶质蛋白,profilin-1(PFN1)和胸腺蛋白酶β-4(TMSB4x)。与两种参考蛋白相比,其他13个蛋白质以相对的方式定量。三倍一次的LC-MRM-MS测量显示MRM峰面积中值CV为5.7%。根据血液收集和等离子体制剂之间的储存时间,PFN1和TMSB4X的量快速增加。它表明细胞组分泄漏到等离子体级分中。相对定量进一步揭示了包括PFN1,S10A8,S10A9,S10A11和TMSB4X的五种蛋白质显示出显着差异(P <0.05)。在典型的临床研究条件下,我们进一步监测为蛋白质诊断收集的40个样本上的PFN1和TMSB4x。与在一天内制备的等离子体样品相比,PFN1和TMSB4x的水平在从前一天收集的血液制备的血浆样品中增加,并在4℃(PFN1和0.98至5.36的0.51至3.11g / ml中保持过夜。 G / ml平均为TMSB4x)。我们的结果表明,确保准确的基于蛋白质的诊断或生物标志物发现和验证的血浆质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号